Moleculin Biotech, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2020-12-31 was 0.00 shares.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2020-09-30 was 0.00 shares.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-09-30 was 0.00 shares.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 0.00 shares.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 0.00 shares.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2020 was 0.00 shares, a 100.00% decline from fiscal 2019.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2019 was 25.00K shares, a 0.00% change from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2022-12-31 | 0.00 shares 10-K · filed 2023-03-22 | |
| 2021-12-31 | 0.00 shares 10-K · filed 2022-03-24 | |
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | 0.00 shares 10-K · filed 2021-03-24 |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | |
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | 25.00K shares 10-K · filed 2020-03-19 |
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | 50.00K shares derived: sum of 4 quarters · filed 2019-11-12 |
| 2019-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-16 | 50.00K shares derived: sum of 4 quarters · filed 2019-08-16 |
| 2019-03-31 | 25.00K shares 10-Q · filed 2019-05-13 | 50.00K shares derived: sum of 4 quarters · filed 2019-05-13 |
| 2018-12-31 | 25.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | 25.00K shares 10-K · filed 2019-02-21 |
| 2018-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | |
| 2018-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | |
| 2018-03-31 | 0.00 shares 10-Q · filed 2018-05-14 | |
| 2017-12-31 | 0.00 shares 10-K · filed 2019-02-21 | |
| 2016-12-31 | 0.00 shares 10-K · filed 2019-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |